Non-HIV Vaccine-Induced Immune Responses as Potential Baseline Immunogenicity Predictors of ALVAC-HIV and AIDSVAX B/E-Induced Immune Responses
Identifying correlations between immune responses elicited via HIV and non-HIV vaccines could aid the search for correlates of HIV protection and increase statistical power in HIV vaccine-efficacy trial designs. An exploratory objective of the HVTN 097 phase 1b trial was to assess whether immune res...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-08-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/16/9/1365 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850258295991828480 |
|---|---|
| author | Ying Huang Shomoita Alam Erica Andersen-Nissen Lindsay N. Carpp One B. Dintwe Britta S. Flach Nicole Grunenberg Fatima Laher Stephen C. De Rosa Guido Ferrari Craig Innes Linda-Gail Bekker James G. Kublin M. Juliana McElrath Georgia D. Tomaras Glenda E. Gray Peter B. Gilbert |
| author_facet | Ying Huang Shomoita Alam Erica Andersen-Nissen Lindsay N. Carpp One B. Dintwe Britta S. Flach Nicole Grunenberg Fatima Laher Stephen C. De Rosa Guido Ferrari Craig Innes Linda-Gail Bekker James G. Kublin M. Juliana McElrath Georgia D. Tomaras Glenda E. Gray Peter B. Gilbert |
| author_sort | Ying Huang |
| collection | DOAJ |
| description | Identifying correlations between immune responses elicited via HIV and non-HIV vaccines could aid the search for correlates of HIV protection and increase statistical power in HIV vaccine-efficacy trial designs. An exploratory objective of the HVTN 097 phase 1b trial was to assess whether immune responses [focusing on those supported as correlates of risk (CoR) of HIV acquisition] induced via the RV144 pox-prime HIV vaccine regimen correlated with those induced via tetanus toxoid (TT) and/or hepatitis B virus (HBV) vaccines. We measured TT-specific and HBV-specific IgG-binding antibody responses and TT-specific and HBV-specific CD4+ T-cell responses at multiple time points in HVTN 097 participants, and we assessed their correlations at peak time points with HIV vaccine (ALVAC-HIV and AIDSVAX B/E)-induced responses. Four correlations were significant [false discovery rate-adjusted <i>p</i>-value (FDR) ≤ 0.2]. Three of these four were with IgG-binding antibody responses to TT measured one month after TT receipt, with the strongest and most significant correlation [rho = 0.368 (95% CI: 0.096, 0.588; <i>p</i> = 0.008; FDR = 0.137)] being with IgG-binding antibody responses to MN gp120 gDneg (B protein boost) measured two weeks after the second ALVAC-HIV and AIDSVAX B/E boost. The fourth significant correlation [(rho = 0.361; 95% CI: 0.049, 0.609; <i>p</i> = 0.021; FDR = 0.137)] was between CD4+ T-cell responses to a hepatitis B surface antigen peptide pool, measured 2 weeks after the third HBV vaccination, and IgG-binding antibody responses to gp70BCaseAV1V2 (B V1V2 immune correlate), measured two weeks after the second ALVAC-HIV and AIDSVAX B/E boost. These moderate correlations imply that either vaccine, TT or HBV, could potentially provide a moderately useful immunogenicity predictor for the ALVAC-HIV and AIDSVAX B/E HIV vaccine regimen. |
| format | Article |
| id | doaj-art-342eca49e116452ab91a719fe4d9dcad |
| institution | OA Journals |
| issn | 1999-4915 |
| language | English |
| publishDate | 2024-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj-art-342eca49e116452ab91a719fe4d9dcad2025-08-20T01:56:13ZengMDPI AGViruses1999-49152024-08-01169136510.3390/v16091365Non-HIV Vaccine-Induced Immune Responses as Potential Baseline Immunogenicity Predictors of ALVAC-HIV and AIDSVAX B/E-Induced Immune ResponsesYing Huang0Shomoita Alam1Erica Andersen-Nissen2Lindsay N. Carpp3One B. Dintwe4Britta S. Flach5Nicole Grunenberg6Fatima Laher7Stephen C. De Rosa8Guido Ferrari9Craig Innes10Linda-Gail Bekker11James G. Kublin12M. Juliana McElrath13Georgia D. Tomaras14Glenda E. Gray15Peter B. Gilbert16Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USAVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USAVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USAVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USAVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USACape Town HVTN Immunology Laboratory, Cape Town 8001, South AfricaVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USAPerinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Soweto, Johannesburg 2193, South AfricaVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USADepartment of Surgery, Duke University, Durham, NC 27705, USAThe Aurum Institute, Klerksdorp 2570, South AfricaThe Desmond Tutu HIV Centre, University of Cape Town, Cape Town 7925, South AfricaVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USAVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USADepartment of Surgery, Duke University, Durham, NC 27705, USASouth African Medical Research Council, Cape Town 7460, South AfricaVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USAIdentifying correlations between immune responses elicited via HIV and non-HIV vaccines could aid the search for correlates of HIV protection and increase statistical power in HIV vaccine-efficacy trial designs. An exploratory objective of the HVTN 097 phase 1b trial was to assess whether immune responses [focusing on those supported as correlates of risk (CoR) of HIV acquisition] induced via the RV144 pox-prime HIV vaccine regimen correlated with those induced via tetanus toxoid (TT) and/or hepatitis B virus (HBV) vaccines. We measured TT-specific and HBV-specific IgG-binding antibody responses and TT-specific and HBV-specific CD4+ T-cell responses at multiple time points in HVTN 097 participants, and we assessed their correlations at peak time points with HIV vaccine (ALVAC-HIV and AIDSVAX B/E)-induced responses. Four correlations were significant [false discovery rate-adjusted <i>p</i>-value (FDR) ≤ 0.2]. Three of these four were with IgG-binding antibody responses to TT measured one month after TT receipt, with the strongest and most significant correlation [rho = 0.368 (95% CI: 0.096, 0.588; <i>p</i> = 0.008; FDR = 0.137)] being with IgG-binding antibody responses to MN gp120 gDneg (B protein boost) measured two weeks after the second ALVAC-HIV and AIDSVAX B/E boost. The fourth significant correlation [(rho = 0.361; 95% CI: 0.049, 0.609; <i>p</i> = 0.021; FDR = 0.137)] was between CD4+ T-cell responses to a hepatitis B surface antigen peptide pool, measured 2 weeks after the third HBV vaccination, and IgG-binding antibody responses to gp70BCaseAV1V2 (B V1V2 immune correlate), measured two weeks after the second ALVAC-HIV and AIDSVAX B/E boost. These moderate correlations imply that either vaccine, TT or HBV, could potentially provide a moderately useful immunogenicity predictor for the ALVAC-HIV and AIDSVAX B/E HIV vaccine regimen.https://www.mdpi.com/1999-4915/16/9/1365binding antibodiesbiomarkersHIV vaccineimmune correlatesT-cell responses |
| spellingShingle | Ying Huang Shomoita Alam Erica Andersen-Nissen Lindsay N. Carpp One B. Dintwe Britta S. Flach Nicole Grunenberg Fatima Laher Stephen C. De Rosa Guido Ferrari Craig Innes Linda-Gail Bekker James G. Kublin M. Juliana McElrath Georgia D. Tomaras Glenda E. Gray Peter B. Gilbert Non-HIV Vaccine-Induced Immune Responses as Potential Baseline Immunogenicity Predictors of ALVAC-HIV and AIDSVAX B/E-Induced Immune Responses Viruses binding antibodies biomarkers HIV vaccine immune correlates T-cell responses |
| title | Non-HIV Vaccine-Induced Immune Responses as Potential Baseline Immunogenicity Predictors of ALVAC-HIV and AIDSVAX B/E-Induced Immune Responses |
| title_full | Non-HIV Vaccine-Induced Immune Responses as Potential Baseline Immunogenicity Predictors of ALVAC-HIV and AIDSVAX B/E-Induced Immune Responses |
| title_fullStr | Non-HIV Vaccine-Induced Immune Responses as Potential Baseline Immunogenicity Predictors of ALVAC-HIV and AIDSVAX B/E-Induced Immune Responses |
| title_full_unstemmed | Non-HIV Vaccine-Induced Immune Responses as Potential Baseline Immunogenicity Predictors of ALVAC-HIV and AIDSVAX B/E-Induced Immune Responses |
| title_short | Non-HIV Vaccine-Induced Immune Responses as Potential Baseline Immunogenicity Predictors of ALVAC-HIV and AIDSVAX B/E-Induced Immune Responses |
| title_sort | non hiv vaccine induced immune responses as potential baseline immunogenicity predictors of alvac hiv and aidsvax b e induced immune responses |
| topic | binding antibodies biomarkers HIV vaccine immune correlates T-cell responses |
| url | https://www.mdpi.com/1999-4915/16/9/1365 |
| work_keys_str_mv | AT yinghuang nonhivvaccineinducedimmuneresponsesaspotentialbaselineimmunogenicitypredictorsofalvachivandaidsvaxbeinducedimmuneresponses AT shomoitaalam nonhivvaccineinducedimmuneresponsesaspotentialbaselineimmunogenicitypredictorsofalvachivandaidsvaxbeinducedimmuneresponses AT ericaandersennissen nonhivvaccineinducedimmuneresponsesaspotentialbaselineimmunogenicitypredictorsofalvachivandaidsvaxbeinducedimmuneresponses AT lindsayncarpp nonhivvaccineinducedimmuneresponsesaspotentialbaselineimmunogenicitypredictorsofalvachivandaidsvaxbeinducedimmuneresponses AT onebdintwe nonhivvaccineinducedimmuneresponsesaspotentialbaselineimmunogenicitypredictorsofalvachivandaidsvaxbeinducedimmuneresponses AT brittasflach nonhivvaccineinducedimmuneresponsesaspotentialbaselineimmunogenicitypredictorsofalvachivandaidsvaxbeinducedimmuneresponses AT nicolegrunenberg nonhivvaccineinducedimmuneresponsesaspotentialbaselineimmunogenicitypredictorsofalvachivandaidsvaxbeinducedimmuneresponses AT fatimalaher nonhivvaccineinducedimmuneresponsesaspotentialbaselineimmunogenicitypredictorsofalvachivandaidsvaxbeinducedimmuneresponses AT stephencderosa nonhivvaccineinducedimmuneresponsesaspotentialbaselineimmunogenicitypredictorsofalvachivandaidsvaxbeinducedimmuneresponses AT guidoferrari nonhivvaccineinducedimmuneresponsesaspotentialbaselineimmunogenicitypredictorsofalvachivandaidsvaxbeinducedimmuneresponses AT craiginnes nonhivvaccineinducedimmuneresponsesaspotentialbaselineimmunogenicitypredictorsofalvachivandaidsvaxbeinducedimmuneresponses AT lindagailbekker nonhivvaccineinducedimmuneresponsesaspotentialbaselineimmunogenicitypredictorsofalvachivandaidsvaxbeinducedimmuneresponses AT jamesgkublin nonhivvaccineinducedimmuneresponsesaspotentialbaselineimmunogenicitypredictorsofalvachivandaidsvaxbeinducedimmuneresponses AT mjulianamcelrath nonhivvaccineinducedimmuneresponsesaspotentialbaselineimmunogenicitypredictorsofalvachivandaidsvaxbeinducedimmuneresponses AT georgiadtomaras nonhivvaccineinducedimmuneresponsesaspotentialbaselineimmunogenicitypredictorsofalvachivandaidsvaxbeinducedimmuneresponses AT glendaegray nonhivvaccineinducedimmuneresponsesaspotentialbaselineimmunogenicitypredictorsofalvachivandaidsvaxbeinducedimmuneresponses AT peterbgilbert nonhivvaccineinducedimmuneresponsesaspotentialbaselineimmunogenicitypredictorsofalvachivandaidsvaxbeinducedimmuneresponses |